

## SUBJECT INDEX TO VOLUME 4

- AIDS .....347  
 anti-HIV natural calanolides against .....351  
 anti-HIV natural products against .....348  
 clinical manifestations of .....347  
 cordatolides against .....355  
 HIV life-cycle in .....348  
 natural/synthetic coumarins against .....358  
 nonnucleoside reverse transcriptase inhibitors  
 against .....349  
 suksdorfin/DCK analogs against .....356
- Animal lentiviruse .....294  
 history of .....294  
 neuropathology of .....295
- Antiretroviral drugs .....3
- Antiretroviral therapy .....431  
 animal models for evaluation of .....431  
 HIV encephalitis SCID model for .....438  
 Simian immunodeficiency virus model for .....432
- APOBEC3 .....401  
 cytidine deaminase activity of .....402  
 HIV Gag interaction of .....403  
 HIV Vif interaction of .....404  
 interaction with HIV-1 .....401  
 interaction with HIV proteins .....403  
 restriction of HIV replication by .....402  
 species specific exclusion by Vif .....404  
 sub-family of .....401
- APOBEC3G .....144  
 antiretroviral activity of .....146  
 characterization of .....144  
 effect of Vif counteracts on .....149  
 effect on endogenous retroelements .....151  
 effect on hepatitis B virus .....151  
 effect on retroviruses .....150  
 incorporation into virion in .....145  
 mediated deamination of HIV-1 cDNA .....144  
 species specificity of .....150  
 Vif mechanism of .....147
- Autoimmunity .....177  
 as component of natural immunity to HIV .....177  
 B cell selection/survival in .....177  
 regulatory mechanisms of .....178
- Biomarkers .....282  
 disease based .....285  
 for HAD .....282  
 integrative testing for .....285
- Blood-brain barrier .....259  
 cytokine transport *via* .....262  
 disruption of .....261  
 efflux of antiretrovirals *via* .....262  
 efflux of virus/viral proteins *via* .....262  
 endothelial cell secretions *via* .....262  
 essentials of .....259  
 in neuroAIDS .....259,261
- mechanisms of entry *via* .....260  
 mechanisms of exit *via* .....261  
 role of .....261  
 viral proteins/oxidative stress in .....262  
 virus/virus protein passage across .....261
- Brain .....249  
 component/structures/cells of .....249
- Calanolide .....353  
 related compounds to .....353  
 synthetic analogs of .....354
- (+)-Calanolide A .....353  
 pharmacokinetic profile of .....353
- Cellular cytidine-deaminases .....141
- Cellular RNA binding proteins .....43  
 in regulation of HIV-1 alternative RNA  
 splicing .....43
- Central nervous system (CNS) disease .....434  
 LP-BM5-induced .....439  
 SIV induced .....434
- Chemokines .....311  
 effect on neural stem/progenitor cells .....311
- Coumarins .....347  
 as inhibitors of HIV reverse transcriptase .....347  
 as nonnucleoside reverse transcriptase  
 inhibitors .....350  
 natural .....358  
 synthetic .....359
- C-type lectin receptors .....170
- Cyclophilin .....156  
 A/Trim5 .....156
- Dendritic cells (DCs) .....169  
 intracellular trafficking of .....171  
 microbicides in .....173  
 role of DC-sign in .....171
- Diabetes .....97  
 electronic medical record systems for .....97
- DNA .....33  
 counteract uracils in .....33
- DNA repair .....411  
 double-strand break DNA repair proteins in .....413  
 in HIV-1 infection .....411
- DSB DNA repair proteins .....417  
 in post-integration repair .....417
- Feline immunodeficiency virus .....298,434  
 antiviral drug testing in .....436  
 based CNS disease .....436

- Fine needle aspiration cytology (FNAC) .....459  
 clinical scoring system as useful as .....459  
 in diagnosis of tuberculous lymphadenitis .....459  
 in HIV positive patients .....459
- Fv-1 (friend virus susceptibility 1) .....153  
 restriction of retroviral infection by .....153
- HAART-persistent HIV-1 reservoirs .....204  
 clinical eradication trials of .....206  
 novel agents for eradication of .....204
- Hepatitis C virus (HCV) .....13,21  
 among HIV-infected patients .....13  
 co-infection of .....13
- Highly active antiretroviral therapy  
 (HAART) .....79,199,221,375,  
 and persistent HIV-1 latent reservoirs .....199  
 associated metabolic syndrome .....79  
 coagulation disorders by .....83  
 dysglycemia by .....82  
 eliminating persistent use of .....202  
 endothelial dysfunction by .....80  
 factors influencing adherence to .....221  
 for HIV infection .....79  
 hypertension by .....82  
 immune activation therapy by .....202  
 in patients with AIDS-related primary central  
 nervous system non-Hodgkin's lymphoma .....375  
 long-term administration of .....201  
 metabolic/cardiovascular complications of .....79  
 risk of cardiovascular disease by .....82  
 vasculitis by .....83
- HIV .....177,191,209,249,267,279,293,365,401  
 and role of endogenous retroviruses .....183  
 animal models of .....293  
 animal models of allo-autoimmunity in .....181  
 anti-cell antibodies in .....179  
 anti-idiotypic network in .....180  
 APOBEC3 pathogenesis of .....405  
 autoimmune connection with .....178,181  
 B cell dysfunction in .....178  
 behavioral approaches for .....212  
 biomedical approaches for .....211  
 cellular tropism of .....269  
 central nervous system parenchymal cells  
 targeted by .....252  
 changes in brain induced by .....254  
 circulating immune complexes (IC) in .....180  
 compartmentalization in CNS .....269  
 drug resistance of .....406  
 effect on regional/cellular organization  
 of brain .....249  
 entry to central nervous system .....253  
 epidemiology among adolescents .....209  
 fitness constraints on immune escape from .....191  
 G-A hypermutation in .....405  
 in disease pathogenesis .....279  
 in nervous system disease .....293  
 lymphocytotoxic antibodies in .....180  
 modes of viral persistence of .....279  
 mononuclear phagocyte interactions with .....279  
 neuroinvasion by .....267  
 oxidative stress in .....182  
 pathogenesis of .....254  
 prevention of sexually transmitted infection  
 in adolescents by .....209  
 protective autoimmunity in .....180  
 role of perivascular macrophages/resident  
 microglia in .....268  
 specific T cells/antibody in .....191  
 studies of allo-vaccination in .....181  
 Trojan exosome hypothesis in .....183  
 types/origin of .....365  
 viral life cycle of .....280
- HIV/AIDS .....12,431  
 and *Tuberculosis* co infection .....13  
 animals models for .....431  
 clinical/epidemiological characteristics of .....12  
 in China .....14  
 in Thailand .....15  
 related drugs in African countries .....14  
 Simian immunodeficiency virus model for .....432
- HIV/HCV coinfection .....21  
 functions of viral proteins in .....22  
 immune evasion mechanisms in .....21  
 quasispecies diversity in .....22  
 viral evolution in .....22
- HIV infection .....87,107  
 ascariasis in .....89  
 cryptosporidiosis in .....91  
 cyclosporiasis in .....93  
*Entamoeba* infestation in .....90  
 enterobiasis in .....89  
 giardiasis in .....93  
 hook worm infestation in .....88  
 impairment of platelet formation/loss .....107  
 increased c-Mpl/ligand thrombopoietin  
 expression in .....107  
 intestinal protozoa infestation in .....90  
 isosporiasis in .....92  
 microsporidiasis in .....92  
 opisthorchiasis in .....89  
 strongyloidiasis in .....87  
 taeniasis in .....90  
 trichuriasis in .....89
- HIV-1 .....65,117,131,169,191,267,307,347,365,387,411  
 adaptive immune control of .....191  
 antigen presentation of .....173  
 anti-HIV natural calanolides against .....351  
 anti-HIV natural products against .....348  
 APOBEC3G against .....123  
 assembly/maturation/budding in .....125  
 cellular antiviral defense against .....119  
 cellular response to double-strand DNA  
 breaks of .....411  
 chemokines/receptors in .....309  
 classification of .....365  
 constraints on immune escape in .....193  
 cordatolides against .....355  
 cyclophilin A against .....122  
 disease progression of .....65  
 dynamics of virus-host interplay in replication

- of .....117
  - effect of TRIM5 $\alpha$  on .....122
  - entry process of .....388
  - envelope glycoproteins of .....387
  - evolution of antigenic/escape variants during
    - infection with .....67
  - fitness cost of viral escape in .....192
  - genetic variation of .....65
  - global genetic variation of .....365
  - host factors involved in .....117
  - host factors involved in late events of
    - replication of .....125
  - host factors of .....393
  - host restriction factors for .....119
  - hypotheses derived from .....131
  - immune escape in .....191
  - in development of HAD .....308
  - infection of .....172
  - inhibitors for .....348
  - inhibitors of attachment of .....388
  - inhibitors of co-receptor engagement of .....390
  - integration/post-integration repair of .....411
  - introduction of HAART in .....307
  - mechanisms of neurotropism by .....267
  - molecular epidemiology of major group M of .....366
  - molecules involved in attachment of .....170
  - natural/synthetic coumarins against .....358
  - neuronal injury in .....312
  - neuropathology of .....308
  - nonnucleoside reverse transcriptase inhibitors
    - against .....349
  - origin/endemicity of .....366
  - reservoirs of .....393
  - reverse transcription/uncoating of .....123
  - role of formation/nuclear translocation of pre-
    - integration complexes of .....123
  - role of Nef to persistent replication of .....69
  - SIV-macaque model for .....65
  - studies of IRES-like activity in .....135
  - suksdorfin/DCK analogs against .....356
  - suppression of replication by inhibitors of
    - double-strand break DNA repair proteins .....417
  - targeting of .....388
  - temporal analysis of variation of .....67
  - to targets dendritic cells for transmission .....169
  - viral replication in CD4<sup>+</sup> T-cell infection by .....68
  - viral transcription of .....125
- HIV-1 associated CNS disease .....319
    - chemokines in .....323
    - CXCR4 in .....323
    - GLIA progenitors in .....320
    - neural progenitors in .....319
  - HIV-1 associated dementia .....307
    - death in .....307
    - mechanisms of neuronal injury in .....307
  - HIV-1 entry inhibitors .....387
    - applications of .....387
    - CCR5 inhibitors as .....390
    - CCR5/CXCR4 inhibitors as .....391
    - classes of .....387
    - CXCR4 inhibitors as .....391
  - factors affecting potency of .....387
  - fusion inhibitors as .....391
  - HIV-1 infection .....423
    - IL-18 binding protein (BP) in .....425
    - innate cytokines in .....423
    - morphologic/metabolic effects in .....426
    - role of IL-18 in .....425
    - Th1/TH2 shift in .....425
  - HIV-1 latency .....199
    - HIV-1 integration in .....199
    - role of chromatin in .....199
    - role of proviral integration sites in .....199
  - HIV-1 mRNA .....44
    - splicing of .....44
  - HIV-1 Nef .....57
    - apoptosis of .....58
    - effects of .....57
    - in vitro* models for .....59
    - in vitro* studies of .....57
    - in vivo* models for .....60
    - modeling thymic type .....57
    - Nef transgenic mice for .....60
    - SCID-HU mice for .....61
    - signaling of .....58
    - trafficking of .....57
  - HIV-1 splicing .....43
    - cell-specific changes in .....50
    - experimental systems for .....43
    - for virus replication .....48
    - in virus infection .....50
    - mechanisms of regulation of .....44
    - requirement of .....48
  - Human disease .....283
    - genomics/proteomics of .....283
    - to determine fingerprints for .....283
  - Infectious synapse .....172
  - Inophyllums .....355
  - Interleukin-18 .....423
    - as proinflammatory cytokine in HIV-1
      - infection .....423
      - in cardiovascular manifestations .....427
      - in fat redistribution .....426
      - in metabolic disorders .....427
  - Intestinal parasite infestation .....87
    - in HIV infected patients .....87
  - Intracellular restriction factors .....141
    - in defense system .....141
    - in mammalian cells .....141
    - of retroviral infection in primate cells .....153
  - Korean red ginseng (KRG) .....447
  - Lentiviruses .....141
    - role of Vif in .....141

Lentivirus-like particles .....	475	Pre-integration complexes (PICs) .....	117
effect on immune responses .....	475	cellular factor associated with .....	124
without reverse transcriptase .....	475		
Lipodystrophy .....	80	Recombinant gp 125 .....	229
mitochondrial dysfunction in .....	80	accessibility of V3 region of .....	229
tumor necrosis factor-alpha (TNF-alpha) in .....	80		
LP-BM5/murine acquired immunodeficiency syndrome (MAIDS) model .....	439	Retrovirus .....	131
		studies of IRES-like activity in .....	136
		translation initiation of .....	131
		Rodent models .....	299
Metabolic encephalopathy .....	282	of HIV nervous system disease .....	299
evolution of .....	282		
Mononuclear phagocytes .....	279	Severe combined immunodeficient (SCID) murine model .....	437
effect on nervous system .....	282		
functional alterations in .....	280	Simian immunodeficiency virus (SIV) .....	65
human immunodeficiency virus interactions with .....	279	and AIDS .....	66
in biomarker discovery .....	279	evolution of antigenic/escape variants during infection with .....	67
Mortality .....	469	genetic variation of .....	65
estimation of .....	469	pathogenicity of emerging variants of .....	70
from vital registrations in South Africa .....	469	phenotype/coreceptor usage of selected variants of .....	69
Mucosal HIV transmission .....	329	temporal analysis of variation of .....	67
genital inflammation/sexual .....	330	viral replication in CD4 <sup>+</sup> T-cell infection by .....	68
microbicides for .....	329		
NNRTIs against .....	330	T cells .....	194
novel broad-spectrum thiourea non-nucleoside inhibitors for .....	329	envelope as target for .....	194
prevention of .....	329		
		Takotsubo-like left ventricular dysfunction .....	239
<i>Nef</i> genes .....	447	in HIV-infected patient .....	239
effect on long-term slow progressors treated with Korean red ginseng .....	447		
high frequency of .....	447	Thiourea NNRTIs .....	330
in HIV-1 .....	447	aromatic/heterocyclic thiazolyl type .....	339
nature of .....	452	binding pocket of .....	332
Neural progenitors .....	319	broad-spectrum type .....	333
definition of .....	320	drug resistance to .....	341
HIV-1 associated central nervous system disease .....	319	heterocyclic ring-substituted .....	336
in adults .....	319	pharmacology/toxicity of .....	340
in children .....	319	phenyl ring-substituted .....	333
location/identification of .....	320	piperidinylethyl/fluorophenethyl thiourea type .....	339
Neurogenic zones .....	321	rational design of tight binding type .....	332
in human .....	321	R-isomers of halopyridyl/thiazolyl type .....	338
Neuronal death .....	309	strategies for design/synthesis of .....	330
chemokines/receptors in .....	309	Thrombocytopenia .....	107
Neuronal dysfunction .....	314	in HIV infection .....	107
treatment or prevention of HIV-1 induced .....	314	Thymus .....	59
Neurotropism .....	270	HIV-1 in .....	59
macrophage tropism predicts .....	270	Nef in .....	59
Neurovirulence .....	271	Thyroid dysfunction .....	463
reduced CCR5/CD4 dependence of neurotropic HIV in .....	271	in Thai HIV-infected patients .....	463
neurotropic HIV in .....	271	prevalence of .....	463
Nonhuman primate lentiviruses .....	296		
as models of HIV-induced nervous system disease .....	296	Uracils .....	31
		against viruses .....	31
		as cellular weapon .....	31
		cellular strategies to .....	33
		in DNA .....	31
		mechanisms of viral escape of .....	31

repair mechanism by HIV-1 virion .....	38	Viral splicing elements .....	43
viral strategies to .....	33		
V1/V2 region .....	229	Zinc finger inhibitor .....	379
deletion of .....	229	antiviral assay of .....	380
Viral DNA .....	34	infectivity assay of .....	380
HIV-1 lentivirus strategy to counteract dUTP		preclinical evaluation of .....	379
misincorporation in .....	35	targeting lentivirus nucleocapsid protein in	
primate HIV-1 lentivirus strategy to counteract		SIV-infected monkeys .....	379
cytosine deamination in .....	34	virucidal assay of .....	380